Hello and welcome to our little slice of the World, a place where passion and opinions run high in our niche area, which just so happens to be the world of patents, innovation, technology, business and other areas of intellectual property. Although Lewis Lee, our founder, is a patent attorney, and many of the contributors to our content are IP counselors, the content should NOT be considered to be legal advice, but rather are intended to be informational. No attorney-client relationship is established through your use of IP Street. For more information please check our Disclaimer, Terms & Conditions and our Privacy Policy.

Here at IPstreet.com, we want to change the story. In fact, we want to help inventors get beyond (1) conceptualization and through the important stages of (2) gestation, (3) early incubation, and (4) late incubation. To help you and your inventions, we also need to help those who support the invention process: patent attorneys, IP portfolio managers, senior executives, and investors. We believe you are the engine that drives economic development, and the supporting cast fuels the innovation process. In this section, you will learn more about how your inventions can be protected and commercialized. Whether you are a new inventor or are a patenting guru, we hope you will find our resources relevant and practical. Our content is developed by subject matter experts in business and IP law; an uncommon union of PhDs and JDs to help you make sense of the IP landscape in the development of your invention, and its ultimate commercialization.

Myopia is generally what happens when unprecedented opportunities are placed before them. Those in the know generally do better than those in the worry. Consider Cetus, a startup biotech with a focus on a liver drug. The FDA delayed the approval of the drug, and a major funding crisis ensued. Chiron offered to take over the liabilities contingent on the sale of two patents (# 4,683,202 and # 4,683,195) to a third party, Roche Molecule for $300M (in 1993). This sale was stalled because DuPont challenged the validity of the patents, based on the formal claims written by the inventor (not a patent attorney), Kary Mullis. In the end, the soap opera turned out well for the investors with weak constitutions. For $300M, they sold the two patents to Roche, turned the company over to Chiron, and walked away. Kary Mullis won the Nobel prize for his invention embedded in these two patents, known as polymerase chain reaction (PCR) which allows DNA to be cloned. Over 4000 patents in biotech cite these original two patents. In our estimation, $300M represents "pennies on the dollar" valuation of these patents. The shareholders got a payday, and left the game. Roche on the other hand is thriving based on its intangible assets. Let IPstreet.com assist you.

Let IP Street help you with your concept search. Once you have drafted the description and claims of the invention, you can utilize our multi-word patent search to see relevant patent documents that have similar textual relationships. This document relevancy search can help you have a better understanding of the patent draft so you can appropriately revise and rewrite to maximize the claim scope. These patent valuation and search tools will help you better develop the patent analytics and potential duration of a patent.

Knowledge is power in developing and implementing strategy. Ignorance is not a defense nor an excuse in attempts to navigate the IP landscape. Utilizing our tools, we can help you understand more about your patent portfolios so that you can executive better business strategies.